What do systematic reviews say?

Any O‐BCS vs mastectomy

It is very uncertain whether any O‐BCS changes disease‐free survival compared with mastectomy (very low certainty).

• Oncoplastic breast‐conserving surgery for women with primary breast cancer 2021 · Cochrane Headline outcomes only
  RR 0.58 [0.41, 0.82]
  1 study · 1193 participants
  Very low

Any O‐BCS vs mastectomy plus reconstruction

It is very uncertain whether any O‐BCS changes disease‐free survival compared with mastectomy plus reconstruction (very low certainty).

• Oncoplastic breast‐conserving surgery for women with primary breast cancer 2021 · Cochrane Headline outcomes only
  HR 0.45 [0.09, 2.22]
  1 study · 317 participants
  Very low

Intervention not reported

The review found no eligible studies for this question.

• Body weight management in overweight and obese breast cancer survivors 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Taxane followed by anthracyclines vs anthracyclines followed by taxane

The review found no eligible studies for this question.

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: Non‐intensive vs intensive follow‐up

Summary of findings: Non‐intensive showed no clear difference in disease‐free survival compared with intensive follow‐up (low certainty).

• Follow‐up strategies for women treated for early breast cancer 2016 · Cochrane Headline outcomes only
  HR 0.84 [0.71, 1]
  2 studies · 2563 participants
  Low

Summary of findings: Decentralised vs centralised follow‐up

Summary of findings: Decentralised showed no clear difference in disease‐free survival compared with centralised follow‐up (moderate certainty).

• Follow‐up strategies for women treated for early breast cancer 2016 · Cochrane Headline outcomes only
  HR 1.06 [0.76, 1.47]
  2 studies · 1264 participants
  Moderate

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines showed no clear difference in disease‐free survival ( compared with anthracyclines followed by taxane (moderate certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  HR 0.84 [0.65, 1.09]
  1 study · 828 participants
  Moderate

Summary of findings table ‐ Postmastectomy radiotherapy (PMRT) vs no PMRT

• Post‐mastectomy radiotherapy for women with early breast cancer and one to three positive lymph nodes 2023 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Capecitabine‐containing regimens vs chemotherapy regimens without capecitabine

Capecitabine‐containing regimens showed no clear difference in disease‐free survivalmedian compared with non‐capecitabine‐containing regimens (high certainty).

• Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer 2021 · Cochrane Headline outcomes only
  HR 1.02 [0.86, 1.21]
  4 studies · 2499 participants
  High

Capecitabine‐containing regimens vs non‐capecitabine‐containing regimens or no chemotherapy

Capecitabine‐containing regimens showed no clear difference in disease‐free survival (DFS)median compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).

• Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer 2021 · Cochrane Headline outcomes only
  HR 0.93 [0.86, 1.01]
  8 studies · 13547 participants
  Moderate

OFS vs no OFS

OFS leads to lower disease‐free survival (DFS) Median compared with no OFS (high certainty).

• Ovarian suppression for adjuvant treatment of hormone receptor‐positive early breast cancer 2020 · Cochrane Headline outcomes only
  HR 0.83 [0.77, 0.9]
  10 studies · 8899 participants
  High

Intervention not reported

The review found no eligible studies for this question.

• Body weight management in overweight and obese breast cancer survivors 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Any O‐BCS vs S‐BCS

Any O‐BCS showed no clear difference in disease‐free survival (up to 5 years) compared with S‐BCS (low certainty).

• Oncoplastic breast‐conserving surgery for women with primary breast cancer 2021 · Cochrane Headline outcomes only
  HR 1.06 [0.89, 1.26]
  7 studies · 5532 participants
  Low

Boost vs no boost

Boost showed no clear difference in disease‐free survival: disease progression/mortality at 5 years compared with no boost (low certainty).

• Tumour bed boost radiotherapy for women after breast‐conserving surgery 2017 · Cochrane Headline outcomes only
  HR 0.94 [0.87, 1.02]
  3 studies · 6549 participants
  Low